0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Serpin A1

Serpin A1

Brief Information

Name:Alpha-1-antiproteinase
Target Synonym:PRO0684,SPAAT,SERPINA1,Alpha-1-antiproteinase,PRO2209,Serpin Family A Member 1,alpha 1-Antitrypsin,Protease Inhibitor 1 (Anti-Elastase), Alpha-1-Antitrypsin,Alpha-1 Protease Inhibitor,Serpin A1,AAT,PI,Serpin Peptidase Inhibitor Clade A (Alpha-1antiprotein
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
SE1-H5226 Human Human Serpin A1 Protein, His Tag
SE1-H5226-structure
SE1-H5226-sds

Synonym Name

SerpinA1,PI,A1A,AAT,PI1,A1AT,MGC9222,PRO2275,MGC23330,alpha1AT,SPAAT

Background

Serpin A1 is also known as Alpha-1-antitrypsin (A1AT), serum trypsin inhibitor, alpha-1 proteinase inhibitor (A1PI), AAT, which belongs to the serpin family. Most serpins inactivate enzymes by binding to them covalently, requiring very high levels to perform their function. Like all serine protease inhibitors, A1AT has a characteristic secondary structure of beta sheets and alpha helices. Serpin A1 / A1AT is inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form of SerpinA1 inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin. Serpin A1 / A1AT protects tissues from enzymes of inflammatory cells, especially neutrophil elastase. Defects in SERPINA1 are the cause of alpha-1-antitrypsin deficiency (A1ATD).

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Alfalastin (LFB SA) Approved Lfb Biotechnologies Alfalastin France alpha 1-Antitrypsin Deficiency Lfb Biotechnologies 2005-08-01 alpha 1-Antitrypsin Deficiency Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
VX-864 VX-864 Phase 2 Clinical Vertex Pharmaceuticals Incorporated alpha 1-Antitrypsin Deficiency Details
Alpha-1 antitrypsin (Kalytera Therapeutics) Clinical Clalit Health Services Details
Belcesiran DCR-A1AT Phase 2 Clinical Dicerna Pharmaceuticals alpha 1-Antitrypsin Deficiency; Liver Diseases Details
ARO-AAT TAK-999; ARO-AAT Phase 2 Clinical Arrowhead Pharmaceuticals alpha 1-Antitrypsin Deficiency Details

This web search service is supported by Google Inc.

totop